NGEx Minerals Drills 20.50m at 17.83% CuEq and 13.50m at 11.36% CuEq at Lunahuasi

NGEx Minerals (TSX: NGEX, OTCQX: NGXXF) reported final results from four Phase 4 drill holes at its 100% owned Lunahuasi copper-gold-silver project in Argentina. Highlights include 20.50m at 17.83% CuEq and 13.50m at 11.36% CuEq, plus other high-grade CuEq intervals. Phase 4 is complete; Phase 5 planning includes an exploration adit and more drilling.

Original reporting
Published Jul 30, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 3:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$NGXXF
Relevance
7/10
AlphAI data visualization · based on juniorminingnetwork.com
Decision brief

The 30-second read

Med
01

Why it matters

The disclosed intersections extend mineralization in multiple directions (southern and northern extensions, plus Mars zone targeting) and the company signals Phase 5 will add an exploration adit and further drilling to grow the system and find additional deposits.

02

Market read

For traders, the actionable element is the fresh set of drill intercepts and the explicit claim that the system remains open, which can drive short-term momentum in a junior explorer.

03

What to watch

The release assumes specific metal prices and 80% recoveries for CuEq; investors may discount CuEq strength until assay QA/QC, metallurgical results, and resource modeling are updated for Phase 5.

Relevance 7/10Novelty 7/10Timing: today’s release of Phase 4 drill results

Background

NGEx is advancing its 100% owned Lunahuasi high-grade copper-gold-silver project in San Juan, Argentina, and this release wraps the final four holes of Phase 4.

Market effects

Supports bullish sentiment for high-grade copper-gold exploration in Argentina and for porphyry-related targets, though impact is likely company-specific.

May modestly improve sentiment toward Argentine copper-gold projects, but no policy/regulatory change is cited.

Limited direct macro linkage; copper and gold price sensitivity remains the main external driver.

Counterpoint

CuEq and high-grade sub-intervals may not translate into a mineable resource without drilling continuity, metallurgy, and eventual resource estimation.

Key entities

  • NGEx Minerals Ltd.

    TSX-listed explorer reporting Phase 4 drill results at Lunahuasi, including multiple high-grade CuEq intervals and open-ended extensions.

  • Lunahuasi project

    100% owned copper-gold-silver project in Argentina where Phase 4 drilling targeted porphyry-related mineralization and Mars zone extensions.

Related articles

$ACNMed

Pentagon AI Security Breach: Accenture Employee Connected Personal Claude Agent, Sensitive Data Flowed Out for Two Months Before Detection

An Accenture employee allegedly connected a personal AI agent to a U.S. Department of Defense system, enabling unauthorized data transfers for two months. The incident involved sensitive unclassified information on NIPRNet, with credentials and network details sent to a third-party site. Accenture denies the claims, while the DoD declined to comment. The breach raises concerns about AI security, compliance, and reporting rules for contractors.

$INTCMed

Intel confirms Nova Lake will use advanced 18A-P node, more details at CES — company says it's taking Panther Lake capacity offline to build more Granite Rapids data center CPUs

Intel's Nova Lake desktop processors will use the 18A-P node, confirmed during Q3 2026 earnings. The company plans to share more details at CES. Intel will take Panther Lake capacity offline to produce more Granite Rapids data center CPUs. Wildcat Lake demand is outpacing supply, and 18A products now make up a third of client CPU revenue. Intel expects a 20% decline in client business next quarter and a 12% PC market decline in 2026.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$IOVAMedAI 8/10

Iovance Reports 24.6% ORR in mNSCLC Trial, Plans Biomarker-Enriched Study

Iovance Biotherapeutics reported a 24.6% response rate in a trial for previously treated non-squamous mNSCLC, with a 59.1% rate in a biomarker-enriched subgroup. The company plans to begin enrollment in a biomarker-enriched study in November 2026 and submit a supplemental Biologics License Application for lifileucel in 2027, according to an SEC filing.